The Role of Targeted therapy in treatment of Non-Hodgkin's Lymphoma
Irtiah Najeeb Abdulaziz;
Abstract
Monoclonal antibody (mAb) therapy with the anti-CD20 mAb rituximab represents one of the most important advances in the treatment of lymphoproliferative disorders in the last 30 years. Prior to its introduction, there had been only modest improvement in t
Other data
| Title | The Role of Targeted therapy in treatment of Non-Hodgkin's Lymphoma | Other Titles | دور العلاج الموجه في علاج لمفوما( الغير – هود جيكن) | Authors | Irtiah Najeeb Abdulaziz | Keywords | The Role of Targeted therapy in treatment of Non-Hodgkin's Lymphoma | Issue Date | 2012 | Description | Monoclonal antibody (mAb) therapy with the anti-CD20 mAb rituximab represents one of the most important advances in the treatment of lymphoproliferative disorders in the last 30 years. Prior to its introduction, there had been only modest improvement in t |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.